Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$1.39 USD

1.39
6,453,360

+0.06 (4.51%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $1.41 +0.02 (1.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 23.53% and 17.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter 2023 results are likely to reflect recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Zacks Equity Research

Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) second-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Zacks Equity Research

McKesson (MCK) to Report Q1 Earnings: Is a Beat in Store?

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Zacks Equity Research

Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Zacks Equity Research

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Zacks Equity Research

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.

Zacks Equity Research

Baxter (BAX) to Post Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Zacks Equity Research

Intuitive Surgical (ISRG) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Zacks Equity Research

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

PacBio (PACB) Gets New Order for Revio System From Bioscientia

by Zacks Equity Research

PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.

Zacks Equity Research

PacBio's (PACB) New Tie-Up to Boost Rare Disease Research

by Zacks Equity Research

PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.

Zacks Equity Research

Here's Why You Should Retain PacBio (PACB) Stock for Now

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

Inari Medical, Inc. (NARI) Down 0.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View

by Zacks Equity Research

PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 6.06% and 10.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy

by Zacks Equity Research

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

PacBio's (PACB) New Offering to Enable High-Throughput Workflows

by Zacks Equity Research

PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.

Zacks Equity Research

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

Pacific Biosciences (PACB) Stock Jumps 18.7%: Will It Continue to Soar?

by Zacks Equity Research

Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

PacBio (PACB) New Revio Workflows to Boost Agricultural Output

by Zacks Equity Research

PacBio (PACB), in collaboration with Corteva Agriscience, is likely to enable groundbreaking plant and microbial long-read sequencing workflow on Revio system.

Zacks Equity Research

Does Pacific Biosciences (PACB) Have the Potential to Rally 30.15% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Pacific Biosciences (PACB) points to a 30.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

PacBio's (PACB) Latest Offering to Enhance Genome Analysis

by Zacks Equity Research

PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.

Zacks Equity Research

PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.